<DOC>
	<DOCNO>NCT00043069</DOCNO>
	<brief_summary>RATIONALE : Preventing bone loss patient undergo androgen ablation prostate cancer may decrease risk fracture may help patient live comfortably . It yet know whether calcium effective without estrogen and/or risedronate prevent osteoporosis . PURPOSE : Randomized phase III trial compare effectiveness two form calcium without estrogen and/or risedronate prevent osteoporosis patient prostate cancer receive androgen ablation therapy .</brief_summary>
	<brief_title>Calcium With Without Estrogen and/or Risedronate Preventing Osteoporosis Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare change bone mineral density patient prostate cancer receive androgen-ablation therapy treat calcium cholecalciferol without conjugate estrogen without risedronate . - Compare toxicity regimens patient . - Compare change bone marker patient treat regimen . - Compare quality life patient treat regimen . - Compare hot flash patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord duration therapy luteinizing hormone-releasing hormone agonist ( 30 day vs 31 150 day vs 151 365 day vs 365 day ) . Patients randomize 1 4 treatment arm . - Arm I : Patients receive oral calcium , oral cholecalciferol , oral risedronate placebo , oral estrogen placebo daily . - Arm II : Patients receive oral calcium , oral cholecalciferol , oral risedronate , oral estrogen placebo daily . - Arm III : Patients receive oral calcium , oral cholecalciferol , low-dose oral conjugate estrogen , oral risedronate placebo daily . - Arm IV : Patients receive oral calcium , oral cholecalciferol , low-dose oral conjugate estrogen , oral risedronate daily . Treatment arm continue 2 year . Quality life assess baseline , monthly 6 month , 1 2 year . Bone mineral density assess baseline , 6 month , 1 2 year . PROJECTED ACCRUAL : A total 282 patient ( 70 per treatment arm ) accrue study within 14 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estrogen Antagonists</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History prostate cancer No evidence metastatic bony disease* NOTE : *Elevated prostatespecific antigen ( PSA ) allow Meets one follow criterion : Currently treatment androgenablation therapy adjuvant set Rising PSA without evidence recurrent disease plan treatment least 6 month No know osteoporosis prior osteoporotic fracture Osteoporosis define bone density hip spine 2.5 standard deviation mean young men PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic SGOT SGPT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase normal OR great 1.5 time ULN normal bone scan Renal Creatinine great 1.5 time ULN No prior symptomatic hypercalcemia hypocalcemia Cardiovascular No active heart disease No congestive heart failure active treatment No myocardial infarction within past 5 year No coronary artery disease ( CAD ) recent myocardial infarction Patients remote history CAD medical treatment ( e.g. , antilipid agent ) allow No prior thrombosis ( deep vein thrombosis , stroke , pulmonary embolism ) know hypercoagulable state cancer Other Fertile patient must use effective contraception Triglycerides great 250 mg/dL ( treatment allow ) Able complete questionnaire ( ) self assistance Able swallow pills No prior hyperlipidemia ( e.g. , prior familial hyperlipidemia fast triglyceride great 250 mg/dL within past 6 month ) No sarcoidosis No parathyroid dysfunction No intolerance bisphosphonates PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics No concurrent systemic steroid Radiotherapy No concurrent radiotherapy Surgery More 3 month since prior concurrent dental extraction , root canal , dental implantation Other No prior bisphosphonates More 5 year since prior percutaneous transluminal coronary angioplasty</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>